Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 13, 2015 3:44 AM ET


Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

37 Employees





Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $400.0K
Chief Medical Officer
Age: 61
Total Annual Compensation: $369.0K
Chief Business Officer
Age: 56
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice President of Research
Age: 51
Total Annual Compensation: $289.3K
Compensation as of Fiscal Year 2014.

Xencor, Inc. Key Developments

Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM

Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.

Xencor's Partner CSL Limited Initiates Phase 2 Clinical Trial of Biologic Candidate Using XmAb Cytotoxic Fc Domain

Xencor, Inc. announced that its partner CSL Limited has initiated, through its licensee Janssen Biotech Inc., a Phase 2 clinical trial for CSL362 (now called JNJ-56022473), which uses Xencor's XmAb Cytotoxic Fc Domain. Xencor will receive an undisclosed milestone payment for the initiation of Phase 2 testing. Under the terms of the agreement signed in February 2009, Xencor granted CSL Limited a non-exclusive license to Xencor Cytotoxic Fc Domains for use in CSL programs, including CSL362. Xencor is also eligible to receive additional milestone payments and royalties on sales. In 2013, CSL Limited licensed CSL362 to Janssen Biotech Inc.

Amgen, Xencor Enter into a Research and License Agreement to Develop Cancer Immunotherapy Treatments

Amgen and Xencor entered into a research and license agreement that could be worth as much as $1.7 billion to develop and commercialize therapeutics focused on cancer immunotherapy and inflammation. Under the partnership, Amgen will be in charge of preclinical and clinical development and commercialization, drawing on its background in protein therapeutics, while Xencor will contribute molecular engineering and bispecific molecules through its trademarked XmAb technology platform. The drug discovery will center on five Amgen-suggested antibody programs, and one specifically dedicated to multiple myeloma. Financially, Amgen will pay Xencor $45 million upfront and up to $1.7 billion for potential clinical, regulatory and sales milestones for six oncology programs, the companies said. Xencor could also receive royalties for developed medications and use of its CD38 bispecific T cell engager.

Similar Private Companies By Industry

Company Name Region
Eppendorf-5 Prime, Inc. United States
Lineagen, Inc. United States
SyAqua Research LLC United States
NEONC Technologies, Inc. United States
NeuroGenetic Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xencor, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at